연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1411. Korean risk assessment model for breast cancer risk prediction.
Park B1, Ma SH, Shin A, Chang MC, Choi JY, Kim S, Han W, Noh DY, Ahn SH, Kang D, Yoo KY, Park SK.
PLoS One. 2013 Oct 25;8(10):e76736. doi: 10.1371/journal.pone.0076736. eCollection 2013.
Link
1410. Dietary intake and breast cancer among carriers and noncarriers of BRCA mutations in the Korean Hereditary Breast Cancer Study.
Ko KP1, Kim SW, Ma SH, Park B, Ahn Y, Lee JW, Lee MH, Kang E, Kim LS, Jung Y, Cho YU, Lee B, Lin JH, Park SK.
Am J Clin Nutr. 2013 Dec;98(6):1493-501. doi: 10.3945/ajcn.112.057760. Epub 2013 Oct 23.
Link
1409. Soluble c-Met protein as a susceptible biomarker for gastric cancer risk: A nested case-control study within the Korean Multicenter Cancer Cohort.
Yang JJ1, Yang JH, Kim J, Ma SH, Cho LY, Ko KP, Shin A, Choi BY, Kim HJ, Han DS, Eun CS, Song KS, Kim YS, Chang SH, Shin HR, Kang D, Yoo KY, Park SK
Int J Cancer. 2013 May 1;132(9):2148-56. doi: 10.1002/ijc.27861. Epub 2012 Oct 25.
Link
1408. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Shin HC1, Han W, Moon HG, Im SA, Moon WK, Park IA, Park SJ, Noh DY.
Ann Surg Oncol. 2013 Aug;20(8):2582-9. doi: 10.1245/s10434-013-2909-6. Epub 2013 Mar 16.
Link
1407. Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society.
Moon HG1, Han W, Kim JY, Kim SJ, Yoon JH, Oh SJ, Yu JH, Noh DY.
Ann Oncol. 2013 Sep;24(9):2298-304. doi: 10.1093/annonc/mdt187. Epub 2013 May 23.
Link
1406. Leptin as a potential target for estrogen receptor-positive breast cancer.
Yom CK1, Lee KM, Han W, Kim SW, Kim HS, Moon BI, Jeong KY, Im SA, Noh DY.
J Breast Cancer. 2013 Jun;16(2):138-45. doi: 10.4048/jbc.2013.16.2.138. Epub 2013 Jun 28.
Link
1405. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
Kim JY1, Han W, Moon HG, Park IA, Ahn SK, Kim J, Lee JW, Kim T, Kim MK, Noh DY.
Clin Breast Cancer. 2013 Oct;13(5):385-91. doi: 10.1016/j.clbc.2013.04.005. Epub 2013 Jul 17.
Link
1404. Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: hypercoagulability in patients with vascular access thrombosis.
Jeong JC, Kim JE, Ryu JW, Joo KW, Kim HK.
Thromb Res. 2013 Nov;132(5):604-9. doi: 10.1016/j.thromres.2013.09.002. Epub 2013 Sep 6.
Link
1403. Decreased thrombomodulin mRNA expression on peripheral monocytes in disseminated intravascular coagulation patients relates to poor outcomes: the ex vivo effects of lipopolysaccharide and thrombin on monocyte thrombomodulin and CD14 mRNA.
Hong SK, Kim JE, Han KS, Kim HK.
Thromb Res. 2013 Sep;132(3):392-7. doi: 10.1016/j.thromres.2013.07.025. Epub 2013 Aug 3.
Link
1402. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays.
Choi Q, Kim JE, Hyun J, Han KS, Kim HK.
Thromb Res. 2013 Jul;132(1):e70-5. doi: 10.1016/j.thromres.2013.05.015. Epub 2013 Jun 13.
Link